Robert V. Rawson

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 322 citations · Full text

Surgical Oncology, Oncology, Prado Trial +10

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

Felicity Newell, Yan Kong, James S. Wilmott et al. · Nature Communications · 2019 · 319 citations · Full text

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M.T. Tetzlaff, Jane L. Messina, Julie E. Stein et al. · Annals of Oncology · 2018 · 252 citations · Full text

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long, Robyn P.M. Saw, Serigne Lo et al. · The Lancet Oncology · 2019 · 182 citations

Neoadjuvant Dabrafenib, Surgical Oncology, Medicine +9

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

Felicity Newell, James S. Wilmott, Peter A. Johansson et al. · Nature Communications · 2020 · 169 citations · Full text